Tempest Therapeutics, Inc. Common Stock
TPSTTempest Therapeutics, Inc. (TPST) is a clinical-stage biotechnology company focused on developing targeted cancer therapies. The company aims to identify and advance novel immuno-oncology and targeted agents, leveraging a deep understanding of tumor biology to create treatments that improve patient outcomes.
Company News
Tempest Therapeutics has agreed to acquire dual-CAR T programs from Factor Bioscience in an all-stock transaction, which is expected to extend the company's operational runway to mid-2027 and diversify its clinical-stage pipeline.
Tempest Therapeutics plans to acquire dual-CAR T programs from Factor Bioscience in an all-stock transaction, expanding its clinical-stage pipeline and extending its operational runway to mid-2027. The acquisition includes a clinical-stage CD19/BCMA dual-CAR T program and is expected to close in early 2026.
The advanced liver cancer market is positioned for strong growth, with over 50 companies developing 52+ pipeline drugs, focusing on innovative targeted therapies and immuno-oncology combinations to improve treatment outcomes.
Tempest Therapeutics, a clinical-stage biotechnology company, announced that it has granted nonqualified stock options to one employee under its 2023 Inducement Plan. The stock options will vest over a four-year period.
Tempest Therapeutics received Orphan Drug Designation from the FDA for its drug amezalpat to treat hepatocellular carcinoma, a type of liver cancer. The drug showed promising results in a Phase 1b/2 clinical study, improving overall survival and response rates compared to the standard of care.
